10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript Bruker Non-GAAP EPS of $0.53 beats by $0.07, revenue of $721.7M misses by $7.34M Bruker Q1 2024 Earnings Preview ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...

These factors together underpin the positive long-term outlook for 10x Genomics. Souda covers the Healthcare sector, focusing on stocks such as Revvity, Exact Sciences, and Natera. According to ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.